keyword
MENU ▼
Read by QxMD icon Read
search

effect of angiotensin 2 on the kidneys

keyword
https://www.readbyqxmd.com/read/28928059/garlic-extract-increases-non-clipped-kidney-tubular-natriuresis-and-diuresis-in-the-2-kidney-1-clip-rat-model-significance-in-hypertension
#1
Khaled K Al-Qattan, Martha Thomson, Muslim Ali
BACKGROUND: Angiotensin II (AngII) is a potent modulator of vascular tone and renal clearance function. Raw garlic aqueous extract (RGAE) inhibits angiotensin I converting enzyme (ACE) dipeptidase activity and therefore AngII generation in the 2-kidney, 1-clip rat model (2K-1Cr). OBJECTIVE: This study investigated the effect of RGAE on the non-clipped kidney clearance function and blood pressure (BP) in the 2 K-1Cr. METHOD: 2K-1Cr were anesthetized, cannulated and instrumentalized and the acute effect during the first hour post-administration of a single intravenous dose of RGAE (30mg/100gb...
September 12, 2017: Pathophysiology: the Official Journal of the International Society for Pathophysiology
https://www.readbyqxmd.com/read/28926934/the-beneficial-effects-of-allicin-in-chronic-kidney-disease-are-comparable-to-losartan
#2
Ehécatl Miguel Ángel García Trejo, Abraham Said Arellano Buendía, Omegar Sánchez Reyes, Fernando Enrique García Arroyo, Raúl Arguello García, María Lilia Loredo Mendoza, Edilia Tapia, Laura Gabriela Sánchez Lozada, Horacio Osorio Alonso
Recent studies suggest that allicin may play a role in chronic kidney disease (CKD), reducing hypertension and oxidative stress and improving renal dysfunction. In the present study, CKD was induced by 5/6 nephrectomy and the animals were divided into four treatment groups as follows: control (C), CKD, CKD+allicin (40 mg/kg pathway oral) (CKDA), and CKD+Losartan (20 mg/kg) (CKDL). After CKD induction, the rats developed hypertension from week 3 to the end of the study. This was associated with increased creatinine and blood urea nitrogen (BUN) levels in serum, increased albuminuria, increased urinary excretion of N-acetyl-β-d-glucosaminidase (NAG), increased nephrin expression, and incrased histological alterations in the cortex...
September 16, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28923834/is-chronic-dialysis-the-right-hard-renal-end-point-to-evaluate-renoprotective-drug-effects
#3
Misghina Weldegiorgis, Dick de Zeeuw, Jamie P Dwyer, Peter Mol, Hiddo J L Heerspink
BACKGROUND AND OBJECTIVES: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components...
September 18, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28911022/hypertensive-cardiovascular-risk-pulsatile-hemodynamics-gender-and-therapeutic-implications
#4
Michel E Safar, Harold Smulyan
PURPOSE: In recent years, the predictive value of 2 pulsatile parameters has been extensively studied in hypertension: aortic stiffness and pulse pressure (PP) amplification. Aortic stiffness is an index of aortic rigidity and PP-amplification is the ratio between central and brachial PP, an indirect evaluation of wave reflections. Both are safe, independent, noninvasive predictors of overall and cardiovascular risk. Our purpose is to determine the validity of these parameters in 2 different circumstances: gender and therapeutic implications...
October 1, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/28904068/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-established-cardiovascular-disease-and-chronic-kidney-disease
#5
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis T George, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman
Background -Empagliflozin, a sodium glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME(®) trial. Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease...
September 13, 2017: Circulation
https://www.readbyqxmd.com/read/28888268/a-randomized-multicenter-open-label-blinded-end-point-trial-comparing-the-effects-of-spironolactone-to-chlorthalidone-on-left-ventricular-mass-in-patients-with-early-stage-chronic-kidney-disease-rationale-and-design-of-the-spiro-ckd-trial
#6
RANDOMIZED CONTROLLED TRIAL
Manvir K Hayer, Nicola C Edwards, Gemma Slinn, William E Moody, Rick P Steeds, Charles J Ferro, Anna M Price, Cecilio Andujar, Mary Dutton, Rachel Webster, David J Webb, Scott Semple, Iain MacIntyre, Vanessa Melville, Ian B Wilkinson, Thomas F Hiemstra, David C Wheeler, Anna Herrey, Margaret Grant, Samir Mehta, Natalie Ives, Jonathan N Townend
BACKGROUND: Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and arterial stiffness. In a previous trial, spironolactone improved these end points compared with placebo in subjects with early-stage CKD, but it is not known whether these effects were specific to the drug or secondary to blood pressure lowering. AIM: The aim was to investigate the hypothesis that spironolactone is superior to chlorthalidone in the reduction of LV mass while exerting similar effects on blood pressure...
September 2017: American Heart Journal
https://www.readbyqxmd.com/read/28877882/mechanotransduction-signaling-in-podocytes-from-fluid-flow-shear-stress
#7
Tarak Srivastava, Hongying Dai, Daniel P Heruth, Uri S Alon, Robert E Garola, Jianping Zhou, R Scott Duncan, Ashraf El-Meanawy, Ellen T McCarthy, Ram Sharma, Mark L Johnson, Virginia J Savin, Mukut Sharma
Recently we and others have found that hyperfiltration-associated increase in biomechanical forces, namely tensile stress and fluid flow shear stress (FFSS) can directly and distinctly alter podocyte structure and function. The ultrafiltrate flow over the major processes and cell body generates FFSS to podocyte. Our previous work suggests that COX2-PGE2-EP2 axis plays an important role in mechanoperception of FFSS in podocyte (Srivastava et al. Am J Physiol Renal Physiol 307: F1323-F1333, 2014). To address mechanotransduction of the perceived mechanical stimulus through EP2 receptor, cultured podocytes were exposed to FFSS (2 dynes/cm2) for 2hrs...
September 6, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28877239/incidence-of-and-risk-factors-for-newly-diagnosed-hyperkalemia-after-hospital-discharge-in-non-dialysis-dependent-ckd-patients-treated-with-ras-inhibitors
#8
Yuki Saito, Hiroyuki Yamamoto, Hideki Nakajima, Osamu Takahashi, Yasuhiro Komatsu
INTRODUCTION: Renin-angiotensin system (RAS) inhibitors have been increasingly prescribed due to their beneficial effects on end-organ protection. Iatrogenic hyperkalemia is a well-known life-threatening complication of RAS inhibitor use in chronic kidney disease (CKD) patients. We hypothesized that CKD patients treated with RAS inhibitors frequently develop hyperkalemia after hospital discharge even if they were normokalemic during their hospitalization because their lifestyles change substantially after discharge...
2017: PloS One
https://www.readbyqxmd.com/read/28874464/mas1-receptor-trafficking-involves-erk1-2-activation-through-a-%C3%AE-arrestin2-dependent-pathway
#9
Flavia M Cerniello, Oscar A Carretero, Nadia A Longo Carbajosa, Bruno D Cerrato, Robson A Santos, Hernán E Grecco, Mariela M Gironacci
The MAS1 receptor (R) exerts protective effects in the brain, heart, vessels, and kidney. R trafficking plays a critical function in signal termination and propagation and in R resensitization. We examined MAS1R internalization and trafficking on agonist stimulation and the role of β-arrestin2 in the activation of ERK1/2 (extracellular signal-regulated kinase 1/2) and Akt after MAS1R stimulation. Human embryonic kidney 293T cells were transfected with the coding sequence for MAS1R-YFP (MAS1R fused to yellow fluorescent protein)...
September 5, 2017: Hypertension
https://www.readbyqxmd.com/read/28873724/combinative-effect-of-sardine-peptides-and-quercetin-alleviates-hypertension-through-inhibition-of-angiotensin-i-converting-enzyme-activity-and-inflammation
#10
Jianming Luo, Cheng Zhang, Qianyue Liu, Shiyi Ou, Lili Zhang, Xichun Peng
Hypertension had relation to angiotensin I converting enzyme (ACE) activity and inflammation. In our previous research, sardine peptides (SP) with ACE inhibitory activity were prepared. However, the combinative effect of SP and quercetin (QC) on hypertension alleviation was still unknown. In the present study, the antihypertensive effect of SP and QC was discovered and the optimal proportion of SP and QC (v/v=8:2, with 20.00mg/mL of SP and 12.99μg/mL of QC for their original concentrations) was screened on ACE activity inhibition in vitro...
October 2017: Food Research International
https://www.readbyqxmd.com/read/28831752/longitudinal-assessment-of-the-effect-of-atrasentan-on-thoracic-bioimpedance-in-diabetic-nephropathy-a-randomized-double-blind-placebo-controlled-trial
#11
David J Webb, Blai Coll, Hiddo J L Heerspink, Dennis Andress, Yili Pritchett, John J Brennan, Mark Houser, Ricardo Correa-Rotter, Donald Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Robert Busch, Pablo Pergola, Hans-Henrik Parving, Dick de Zeeuw
BACKGROUND: Fluid retention is a common adverse event in patients who receive endothelin (ET) receptor antagonist therapy, including the highly selective ETA receptor antagonist, atrasentan. OBJECTIVE: We performed longitudinal assessments of thoracic bioimpedance in patients with type 2 diabetes mellitus and nephropathy to determine whether a decrease in bioimpedance accurately reflected fluid retention during treatment with atrasentan. STUDY DESIGN: We conducted a randomized, double-blind, placebo-controlled study in 48 patients with type 2 diabetes mellitus and nephropathy who were receiving stable doses of renin angiotensin system inhibitors and diuretics...
August 22, 2017: Drugs in R&D
https://www.readbyqxmd.com/read/28830083/metoprolol-increases-uric-acid-and-risk-of-gout-in-african-americans-with-chronic-kidney-disease-attributed-to-hypertension
#12
Stephen P Juraschek, Lawrence J Appel, Edgar R Miller
BACKGROUND: There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk. METHODS: In the African American Study of Kidney Disease and Hypertension (AASK) trial, African Americans with chronic kidney disease were randomly assigned to metoprolol (a beta-blocker), ramipril (an angiotensin-converting enzyme inhibitors [ACEi]), or amlodipine (a dihydropyridine calcium-channel blocker)...
September 1, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/28802945/effect-of-dual-compared-to-no-or-single-renin-angiotensin-system-blockade-on-risk-of-renal-replacement-therapy-or-death-in-predialysis-patients-prepare-2-study
#13
Pauline W M Voskamp, Friedo W Dekker, Merel van Diepen, Ellen K Hoogeveen
Current guidelines on hypertension treatment in chronic kidney disease (CKD) patients discourage combined angiotensin-converting enzyme inhibitor (ACEi) and angiotensin II receptor blocker (ARB) use due to the risk of an increased kidney function decline. However, dual compared to single renin-angiotensin system (RAS) blockade may have more efficacy with regard to hypertension and proteinuria. Among incident predialysis patients (CKD 4-5), we compared dual with no or single RAS blockade regarding kidney function decline and risk of renal replacement therapy (RRT) or death...
July 22, 2017: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/28764919/effects-of-higher-quality-of-care-on-initiation-of-long-term-dialysis-in-patients-with-ckd-and-diabetes
#14
Hon-Yen Wu, Shingo Fukuma, Sayaka Shimizu, Edward C Norton, Yu-Kang Tu, Kuan-Yu Hung, Mei-Ru Chen, Kuo-Liong Chien, Shunichi Fukuhara
BACKGROUND: The burden of diabetes-related chronic kidney disease (CKD) on individuals and society is increasing, shifting attention toward improving the quality of care for patients with CKD and diabetes. We assessed the quality of CKD care and its association with long-term dialysis, acute kidney injury (AKI), and death. STUDY DESIGN: Retrospective cohort study (2004-2011). SETTING & PARTICIPANTS: Adults in Taiwan with incident CKD enrolled in the Longitudinal Cohort of Diabetes Patients...
July 29, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28763548/effect-of-oral-methylprednisolone-on-clinical-outcomes-in-patients-with-iga-nephropathy-the-testing-randomized-clinical-trial
#15
RANDOMIZED CONTROLLED TRIAL
Jicheng Lv, Hong Zhang, Muh Geot Wong, Meg J Jardine, Michelle Hladunewich, Vivek Jha, Helen Monaghan, Minghui Zhao, Sean Barbour, Heather Reich, Daniel Cattran, Richard Glassock, Adeera Levin, David Wheeler, Mark Woodward, Laurent Billot, Tak Mao Chan, Zhi-Hong Liu, David W Johnson, Alan Cass, John Feehally, Jürgen Floege, Giuseppe Remuzzi, Yangfeng Wu, Rajiv Agarwal, Hai-Yan Wang, Vlado Perkovic
Importance: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. Objective: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. Design, Setting, and Participants: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1...
August 1, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28762163/polycystin-2-dependent-cardio-protective-mechanisms-revealed-by-cardiac-stress
#16
Esther Giehl, Fernanda O Lemos, Yan Huang, Frank J Giordano, Ivana Y Kuo, Barbara E Ehrlich
Although autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of multiple kidney cysts, the most frequent cause of death in ADPKD patients is cardiovascular disease. ADPKD is linked to mutations in PKD1 or pkd2, the genes that encode for the proteins polycystin 1 and polycystin 2 (PC1 and PC2, respectively). The cardiovascular complications have been assumed to be a consequence of renal hypertension and activation of renin/angiotensin/aldosterone (RAAS) pathway. However, the expression of PC1 and PC2 in cardiac tissue suggests additional direct effects of these proteins on cardiac function...
July 31, 2017: Pflügers Archiv: European Journal of Physiology
https://www.readbyqxmd.com/read/28753930/pregnancy-proteinuria-plant-based-supplemented-diets-and-focal-segmental-glomerulosclerosis-a-report-on-three-cases-and-critical-appraisal-of-the-literature
#17
Rossella Attini, Filomena Leone, Benedetta Montersino, Federica Fassio, Fosca Minelli, Loredana Colla, Maura Rossetti, Cristiana Rollino, Maria Grazia Alemanno, Antonella Barreca, Tullia Todros, Giorgina Barbara Piccoli
Chronic kidney disease (CKD) is increasingly recognized in pregnant patients. Three characteristics are associated with a risk of preterm delivery or small for gestational age babies; kidney function reduction, hypertension, and proteinuria. In pregnancy, the anti-proteinuric agents (ACE-angiotensin converting enzyme-inhibitors or ARBS -angiotensin receptor blockers) have to be discontinued for their potential teratogenicity, and there is no validated approach to control proteinuria. Furthermore, proteinuria usually increases as an effect of therapeutic changes and pregnancy-induced hyperfiltration...
July 19, 2017: Nutrients
https://www.readbyqxmd.com/read/28743805/ephrinb2-regulates-cardiac-fibrosis-through-modulating-the-interaction-of-stat3-and-tgf-%C3%AE-smad3-signaling
#18
Sheng-An Su, Du Yang, Yue Wu, Yao Xie, Wei Zhu, Zhejun Cai, Jian Shen, Zurong Fu, Yaping Wang, Liangliang Jia, Yidong Wang, Jian-An Wang, Meixiang Xiang
RATIONALE: Cardiac fibrosis is a common feature in left ventricular remodeling that leads to heart failure, regardless of the cause. EphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression. Recently, EphrinB2 was reported to protect kidneys from injury-induced fibrogenesis. However, its role in cardiac fibrosis remains to be clarified...
September 1, 2017: Circulation Research
https://www.readbyqxmd.com/read/28741050/risk-factors-for-progression-of-chronic-kidney-disease-in-the-eppic-trials-and-the-effect-of-ast-120
#19
Gerald Schulman, Tomas Berl, Gerald J Beck, Giuseppe Remuzzi, Eberhard Ritz, Miho Shimizu, Mami Kikuchi, Yuko Shobu
BACKGROUND: Two randomized, double-blind, placebo-controlled trials (EPPIC-1 and EPPIC-2) investigated the efficacy and safety of AST-120, an oral spherical carbon adsorbent, in adults with chronic kidney disease (CKD). While the benefit of adding AST-120 to standard therapy was not supported by these trials, we performed a post hoc analysis to focus on CKD progression and to determine the risk factors for the primary endpoint in the EPPIC trial population. METHODS: In the EPPIC trials, patients were randomly assigned 1:1 to treatment with AST-120 or placebo...
July 24, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28736557/the-effect-of-admission-renal-function-on-the-treatment-and-outcome-of-patients-with-acute-coronary-syndrome
#20
Zach Rozenbaum, Sydney Benchetrit, Saar Minha, Yoram Neuman, Meital Shlezinger, Ilan Goldenberg, Morris Mosseri, David Pereg
BACKGROUND: Chronic kidney disease is a frequent comorbidity among patients with acute coronary syndrome (ACS). We aimed to evaluate treatment characteristics in ACS patients according to their renal function and to assess the effect of differences in therapy on clinical outcomes. METHODS: Included were patients with ACS enrolled in the biennial Acute Coronary Syndrome Israeli Surveys (ACSIS) during 2000-2013. Excluded were patients with cardiogenic shock at presentation...
June 2017: Cardiorenal Medicine
keyword
keyword
114527
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"